Biomolecular markers as determinants of patients selection for adjuvant chemotherapy of sporadic colorectal cancers
- PMID: 20737746
Biomolecular markers as determinants of patients selection for adjuvant chemotherapy of sporadic colorectal cancers
Abstract
Colorectal cancer (CRC) is a disease classified and based on genetic alteration resulting from interaction of environmental factors, individual cancer susceptibility and accumulated somatic changes of the colorectal epithelium. Advanced knowledge in genetics and epigenetics of colorectal cancer develops a hypothesis that various clinical manifestations of colorectal cancer are caused by different carcinogenesis pathways. Different carcinogenesis pathways and types of colorectal cancer appear to bring effects on different response against chemotherapy and prognosis. Chemotherapy is mainly provided for patients with stage III CRC which are also the largest proportion of CRC patients in Indonesia. However, it is also provided for some patients with high risk stage II CRC. Classically, clinical factors have been generally accepted as prognostic factors including depth of tumor invasion, regional nodal metastasis, vascular invasion, poor differentiation, and serologic tumor marker such as carcinoembryonic antigen (CEA). However, clinical and histopathological factors themselves do not provide accurate prediction for colorectal cancer prognosis and treatment. A biomolecular marker is necessary to provide such prediction. Numerous studies have been conducted to evaluate the molecular biological markers in order to determine either the possibility of successful treatment for colorectal cancer (predictive factor) or life-expectancy (prognostic factor). Results of several studies demonstrate different status of some molecular markers to determine successful treatment between stage II and stage III colorectal cancer. Certainly, such finding should be followed up but it shall be accepted that there will be a shift of paradigm of CRC treatment. Therefore, the success of colorectal cancer, excluding the patient's socioeconomic factors and the surgeon's skill, will depend extremely on molecular parameter and not only the stage.
Similar articles
-
Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.Ann Surg. 2007 Dec;246(6):1040-6. doi: 10.1097/SLA.0b013e318142d918. Ann Surg. 2007. PMID: 18043108
-
Factors predicting survival in surgical palliative resection of stage IV colorectal cancer.Minerva Chir. 2009 Jun;64(3):303-6. Minerva Chir. 2009. PMID: 19536056
-
P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.Clin Cancer Res. 2001 May;7(5):1343-9. Clin Cancer Res. 2001. PMID: 11350904
-
[Biomolecular prognostic factors in colorectal cancer].Chir Ital. 2006 Nov-Dec;58(6):733-42. Chir Ital. 2006. PMID: 17190278 Review. Italian.
-
Biologic behavior of microsatellite-unstable colorectal cancer and treatment with 5-fluorouracil.Isr Med Assoc J. 2005 Aug;7(8):520-4. Isr Med Assoc J. 2005. PMID: 16106779 Review.
Cited by
-
Potential prognostic and predictive value of UBE2N, IMPDH1, DYNC1LI1 and HRASLS2 in colorectal cancer stool specimens.Biomed Rep. 2023 Feb 7;18(3):22. doi: 10.3892/br.2023.1604. eCollection 2023 Mar. Biomed Rep. 2023. PMID: 36846616 Free PMC article.
-
Discovery of genes from feces correlated with colorectal cancer progression.Oncol Lett. 2016 Nov;12(5):3378-3384. doi: 10.3892/ol.2016.5069. Epub 2016 Aug 31. Oncol Lett. 2016. PMID: 27900008 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical